Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. - Muñoz-Vendrell A; Arroyo-Pereiro P; León I; Bau L; Matas E; Romero-Pinel L; Roca-Pereira S; Martínez-Yélamos A; Martínez-Yélamos S (Journal of neurology, 2026)